GlobeNewswire by notified

Results of ING’s 2022 Annual General Meeting

Share

Results of ING’s 2022 Annual General Meeting

The Annual General Meeting (AGM) of ING Groep N.V. was held today in Amsterdam. The AGM adopted all agenda items, including the annual accounts for 2021, discharge of the (former) members of the Executive Board and the Supervisory Board, the dividend for 2021 and a reduction the issued share capital of ING Group by cancelling the ordinary shares that were repurchased under the share buyback programme that was completed in February 2022.

Note for editors

For further information on ING, please visit www.ing.com. Frequent news updates can be found in the Newsroom or via the @ING_news Twitter feed. Photos of ING operations, buildings and its executives are available for download at Flickr. ING presentations are available at SlideShare.

Press enquiries Investor enquiries
Raymond Vermeulen ING Group Investor Relations
+31 20 576 6369 Investor.Relations@ing.com
Raymond.Vermeulen@ing.com
ING PROFILE
ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank. The purpose of ING Bank is empowering people to stay a step ahead in life and in business. ING Bank’s more than 57,000 employees offer retail and wholesale banking services to customers in over 40 countries.

ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).


Sustainability forms an integral part of ING’s strategy, evidenced by ING’s leading position in sector benchmarks. ING's ESG rating by MSCI was affirmed 'AA' in December 2021. ING Group shares are included in major sustainability and Environmental, Social and Governance (ESG) index products of leading providers STOXX, Morningstar and FTSE Russell. In January 2021, ING received an ESG evaluation score of 83 ('strong') from S&P Global Ratings.




IMPORTANT LEGAL INFORMATION
Elements of this press release contain or may contain information about ING Groep N.V. and / or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014.



Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those in such statements due to a number of factors, including, without limitation: (1) changes in general economic conditions and customer behaviour, in particular economic conditions in ING’s core markets, including changes affecting currency exchange rates (2) the effects of the Covid-19 pandemic and related response measures, including lockdowns and travel restrictions, on economic conditions in countries in which ING operates, on ING’s business and operations and on ING’s employees, customers and counterparties (3) changes affecting interest rate levels (4) any default of a major market participant and related market disruption (5) changes in performance of financial markets, including in Europe and developing markets (6) political instability and fiscal uncertainty in Europe and the United States (7) discontinuation of or changes in ‘benchmark’ indices (8) inflation and deflation in our principal markets (9) changes in conditions in the credit and capital markets generally, including changes in borrower and counterparty creditworthiness (10) failures of banks falling under the scope of state compensation schemes (11) non-compliance with or changes in laws and regulations, including those concerning financial services, financial economic crimes and tax laws, and the interpretation and application thereof (12) geopolitical risks, political instabilities and policies and actions of governmental and regulatory authorities (13) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (14) prudential supervision and regulations, including in relation to stress tests and regulatory restrictions on dividends and distributions, (also among members of the group) (15) regulatory consequences of the United Kingdom’s withdrawal from the European Union, including authorizations and equivalence decisions (16) ING’s ability to meet minimum capital and other prudential regulatory requirements (17) changes in regulation of US commodities and derivatives businesses of ING and its customers (18) application of bank recovery and resolution regimes, including write-down and conversion powers in relation to our securities (19) outcome of current and future litigation, enforcement proceedings, investigations or other regulatory actions, including claims by customers who feel mislead and other conduct issues (20) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws, including FATCA (21) operational risks, such as system disruptions or failures, breaches of security, cyber-attacks, human error, changes in operational practices or inadequate controls including in respect of third parties with which we do business (22) risks and challenges related to cybercrime including the effects of cyber-attacks and changes in legislation and regulation related to cybersecurity and data privacy (23) changes in general competitive factors, including ability to increase or maintain market share (24) the inability to protect our intellectual property and infringement claims by third parties (25) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (26) changes in credit ratings (27) business, operational, regulatory, reputation and other risks and challenges in connection with climate change (28) inability to attract and retain key personnel (29) future liabilities under defined benefit retirement plans (30) failure to manage business risks, including in connection with use of models, use of derivatives, or maintaining appropriate policies and guidelines (31) changes in capital and credit markets, including interbank funding, as well as customer deposits, which provide the liquidity and capital required to fund our operations, and (32) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures, including press releases, which are available on www.ING.com.



This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only, and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of, or take any responsibility for, any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document, or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING’s control.



Any forward looking statements made by or on behalf of ING speak only as of the date they are made, and ING assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason.



This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Global COVID-19 Memorial Will Honor Pandemic Frontline & Essential Workers24.4.2024 16:18:34 CEST | Press release

CHICAGO, April 24, 2024 (GLOBE NEWSWIRE) -- A monument park and website honoring medical frontline and essential workers worldwide who risked their lives during the COVID-19 pandemic will break ground this summer in Chicago, Illinois. The COVID-19 Monument of Honor, Remembrance, and Resilience draws attention to the enormous sacrifices made by these workers and the stress they encountered. Further, the COVID-19Monument pays tribute to those who lost the battle to COVID-19, now more than seven million individuals. Accessible 24/7, the monument park and website will serve as a gathering space of healing, reflection, & wellness. The website will invite participation from all, and preserve the oral history of essential workers, pandemic survivors (especially those suffering from Long-COVID) and serve as a permanent memorial to lost loved ones. Sally Metzler, Ph.D., the Chair of the Commission, emphasized the epic nature of the impact of the pandemic, “No other event in recent history has t

Fly Play hf.: Increase of share capital24.4.2024 16:16:35 CEST | Press release

Reference is made to the announcement of Fly Play hf. (“PLAY” or the “Company”) on April 11, 2024, regarding the results of a funding round. In a meeting held today, the Company’s Board of Directors decided to exercise the authority granted by the AGM to increase the Company’s share capital by issuing new shares by up to 1,200,000,000 shares in nominal value. As previously announced, the total amount of the authorization will not be used. The Company's Board of Directors decided at a meeting today to increase the Company's share capital by issuing 1,023,155,559 new shares, each with a nominal value of 1 ISK. The new shares will be delivered to investors on April 29, 2024, and admission to trading of the new shares on Nasdaq First North Growth Market Iceland is scheduled to commence on the same day under the symbol PLAY (ISIN: IS0000032936). Following the share capital increase, PLAY has 1,891,598,895 shares outstanding.

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting24.4.2024 16:14:55 CEST | Press release

NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial evaluating the company’s therapeutic cancer vaccine candidate UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab as first-line treatment in unresectable or metastatic malignant melanoma. The trial was conducted at 39 hospitals across the U.S., U.K., Belgium, and Norway, and 156 patients were enrolled between June 2020 and July 2022. The poster presentation features key findings and analyses after a minimum 18-month follow-up of the patients in the trial. Presentation Details: Abstract Num

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting24.4.2024 16:00:00 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on May 31- June 4, 2024. Rapid oral presentation: Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 202424.4.2024 15:55:00 CEST | Press release

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2024 Siili Solutions Plc Stock exchange release 24 April 2024 at 16:55 This is a correction to the stock exchange release published by Siili Solutions Plc on 24 April 2024 at 9:45 am by which the company published its business review for the period 1 January – 31 March 2024. In section “Key events for January-March” it was stated that “75% of Siili employees have completed a GenAI certificate”. The correct information is that “51% of Siili employees in Finland have completed a GenAI certificate”. In addition, in the CEO review it was stated that “By the end of March, 75% of Siili’s employees in Finland had achieved the first-level certification.” The completion percentage was incorrect and the correct information is that “By the end of March, 51% of Siili’s employees in Finland had achieved the first-level certification.” The corrected release is stated below as a whole and the revised repo

HiddenA line styled icon from Orion Icon Library.Eye